REEV.

Here is the inconvenient arithmetic. Roughly fifty million people live with a walking disorder of neurological origin. The therapy that helps them happens inside specialized centers, on expensive equipment, supervised by clinicians whose time is finite. The patient improves. Then the session ends, the harness comes off, and the hardest part - the rest of life - begins without any of it.

Traditional orthotics tried to fill that gap. They are passive: a clever arrangement of springs and braces that hold a joint in place. Helpful, but stubborn. A passive brace cannot tell whether you are climbing stairs or sitting down for dinner; it offers the same resistance to both. It does not learn. It does not adapt. It is, in the most literal sense, brace yourself.

REEV's founders looked at that gap and saw an engineering problem wearing a medical coat. What if the orthosis could read the wearer's intention in real time and respond, the way a good dance partner anticipates the next step rather than fighting it?

Amaury Ciurana and Robin Temporelli did not come from medicine. They came from the world of jet engines and satellites - ISAE-SUPAERO, Airbus, Safran. Ciurana, the CEO, had collected an almost suspiciously tidy run of credentials (Polytechnique, HEC, UC Berkeley) and a one-million-euro Lopez-Loreta academic prize before deciding the most interesting machine to build was one that helps a human walk. Temporelli, the CTO, brought a Ph.D., three patents, and the mechatronics instinct that a knee is, at heart, a control loop with consequences.

Their bet, made in 2021, was that the techniques used to keep an aircraft stable - sensing, prediction, fast actuation - could be miniaturized and pointed at the human gait. That you could measure a person's specific walking signature, feed it to an algorithm, and have a motor deliver assistance milliseconds before the foot needs it. In aerospace, being late by a millisecond is a crash. In walking, it is a stumble. The discipline transfers.

In 2023 they joined Techstars, crossed the Atlantic, and planted a second flag in Boston - close enough to MIT and Boston University to borrow their clinical brains.

The trick that makes DREEVEN more than a heavy brace is the prediction. By reading a person's individual gait signature, the system anticipates the next phase of the step and acts ahead of it. Done right, the wearer stops feeling the weight of the machine and starts feeling like the machine is, quietly, on their side. The hydraulics do the arguing so the human does not have to.

A robot strapped to a recovering body had better be more than a good story, and REEV seems to know it. The validation is being done where it is hardest to fake. MIT's clinical research center has been evaluating the accuracy of REEV SENSE. A clinical study of DREEVEN runs at Boston University's Sargent College, inside the Neuromotor Recovery Laboratory, under Dr. Lou Awad - a movement scientist who joined REEV as clinical lead rather than waving from the sidelines.

Then there is the regulatory grind. The February 2025 round was explicitly earmarked to finalize DREEVEN's design and prepare for FDA trials - the long, unglamorous corridor every medical device must walk before a patient ever does. To get DREEVEN closer to real clinics, REEV set up a Neuro-Integration Program with Stroke Centers of Excellence, the institutions that will eventually decide whether the device earns a place in the recovery routine.

REEV's stated values read like a startup's, until you remember the stakes: social impact, ambition, autonomy, excellence, humility, persistence. The word that does the most work there is autonomy. Not the self-driving kind - the human kind. Getting to the bathroom alone. Walking to the corner without rehearsing it. Standing for a photo without calculating the risk.

The company frames its target as roughly fifty million people whose mobility was edited by neurology. That is not a market in the usual sense; it is a backlog of small, daily indignities the founders think a well-designed machine can quietly delete. Whether DREEVEN ultimately scales to that number is unproven - it is still pre-FDA, still in the clinic. The bet is that the engineering is ready, and that the patience will hold.

Return to that room. The person who had a stroke is on their feet, and the motor that helped is already quiet again, waiting for the next intention. There was no triumphant music, no headline. Just a stand, completed. If REEV is right, that quietness scales. The clinic stops being the only place recovery happens. The brace stops being a cage and becomes a collaborator. Walking stops being a project and goes back to being a reflex.

None of this is guaranteed. Medical devices fail trials. Funding has a temper. Hydraulics leak. But the shape of the wager is clear and unusually honest: take the prediction-and-control discipline that keeps aircraft in the sky, shrink it, strap it to a human leg, and give fifty million people back the smallest, largest freedom there is. The next step. And then the one after that.